Companies · Pharmaceuticals
WARMINSTER · Pharmaceuticals
Diligence memoA one-page analyst read on I 3 Pharmaceuticals, LLC — recommendation, valuation, rhythm, risks.→I 3 Pharmaceuticals, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
I 3 Pharmaceuticals, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
I 3 Pharmaceuticals, LLC is one of 1613 Pharmaceuticals companies tracked from WARMINSTER. By capital raised it ranks mid-pack (ahead of 63% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 63% of sector peers (real $). Modeled value above 73% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 51.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| MedAvail Holdings, Inc. | Series B | $52.9M | $679.3M | 5.23× |
| Revalesio Corp | Series B | $103.4M | $624.8M | 4.81× |
| Kinaset Therapeutics, Inc. | Series B | $30.0M | $438.1M | 3.37× |
| Venatorx Pharmaceuticals, Inc. | Series B | $124.3M | $421.0M | 3.24× |
| Cxl Ophthalmics, Inc. | Series B | $26.4M | $370.1M | 2.85× |
| Delex Healthcare Group, Inc. | Series B | $40.0M | $341.1M | 2.63× |
| Comanche Biopharma Corp. | Series B | $73.6M | $325.9M | 2.51× |
| Petros Pharmaceuticals, Inc. | Series B | $41.7M | $308.0M | 2.37× |
| I 3 Pharmaceuticals, LLC this company | Series B | $16.0M | $262.5M | 2.02× |
| Relay Therapeutics, Inc. | Series B | $30.0M | $253.2M | 1.95× |
| Capacity Bio, Inc. | Series B | $19.2M | $246.0M | 1.89× |
| MediWound Ltd. | Series B | $30.5M | $243.4M | 1.87× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series B | $16.0M | 2022-05-06 | $88.9M | $262.5M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Dhirubhai Kishan Bhagat | — | — | 2022-05 |
| Douglas S. Hamilton | — | — | 2022-05 |
| Jayantilal V. Dhaduk | — | — | 2022-05 |
| Ram Kishan Kallur | — | — | 2022-05 |
I 3 Pharmaceuticals, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Journey Colab Corp. | Pharmaceuticals | Series B | $15.7M | $351.6M | same sector · same stage |
| Land Medicine Inc. | Pharmaceuticals | Series B | $16.9M | $98.0M | same sector · same stage |
| Clarus Therapeutics Holdings, Inc. | Pharmaceuticals | Series B | $15.0M | $289.4M | same sector · same stage |
| Tellus Therapeutics, Inc. | Pharmaceuticals | Series B | $18.0M | $212.5M | same sector · same stage |
| Capacity Bio, Inc. | Pharmaceuticals | Series B | $19.2M | $246.0M | same sector · same stage |
| Stemtrix Corp. | Pharmaceuticals | Series B | $20.0M | $242.3M | same sector · same stage |
| DalCor Pharmaceuticals US, LLC | Pharmaceuticals | Series B | $20.4M | $131.0M | same sector · same stage |
| Stream Biomedical, Inc. | Pharmaceuticals | Series B | $21.5M | $412.2M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Trio Pharmaceuticals, Inc. | Biotech / Pharma | Seed | $22.5M | 83% |
| T3D Therapeutics, Inc. | Pharmaceuticals | Series A | $70.9M | 81% |
| IMC Corp | Pharmaceuticals | Series A | $154.9M | 80% |
| Ten63 Therapeutics, Inc. | Pharma | Seed | $62.5M | 79% |
| PharmID, Inc. | Pharmaceuticals | Series A | $154.9M | 78% |
| Complexa Inc. | Pharmaceuticals | Series C | $386.0M | 78% |
| IRR, Inc. | Pharmaceuticals | Pre-Seed | $7.1M | 78% |
| InMed Pharmaceuticals Inc. | Pharmaceuticals | Series A | $63.7M | 78% |
See where I 3 Pharmaceuticals, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at I 3 Pharmaceuticals, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.